EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Conditions: Ovarian Carcinosarcoma; Uterine Carcinosarcoma Interventions: Drug: Eribulin Mesylate; Drug: Pembrolizumab Sponsors: Australia New Zealand Gynaecological Oncology Group; Eisai Inc.; Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Australia Health | Cancer & Oncology | Carcinosarcoma | New Zealand Health | OBGYN | Ovaries | Research